Jump to content


More on Ponatinib and Next Steps - Harry Erba, MD

  • Please log in to reply
1 reply to this topic

#1 GerryL


    New Member

  • Members
  • Pip
  • 0 posts

Posted 07 November 2013 - 08:07 PM

More on Ponatinib and Next Steps - Harry Erba, MD


Published on Nov 7, 2013

Harry Erba, MD, Director of the Hematological Malignancies Program at the University of Alabama at Birmingham shares more insights into the latest news on Iclusig (Ponatinib) and important information for the days ahead. He shares some background information on the drug's efficacy in CML treatment and discusses the process of submitting the individual Investigational New Drug (IND) application that will be required to access the drug.

#2 Happycat


    New Member

  • Members
  • Pip
  • 5 posts

Posted 13 November 2013 - 05:01 AM

Thanks for posting this, Gerry. That was very informative and gives a good "real world" view of how patients who need ponatinib can still get access. I do hope the FDA fast-tracks the IND applications for individual use.


1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users